• Archives:
    17articles
    Sort by
    Mosted Viewed
    Open Access
    Review
    Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease
    Non-alcoholic fatty liver disease (NAFLD) remains a major cause of chronic liver disease worldwide. Despite extensive studies, the heterogeneity of the risk factors as well as different disease mech...
    Noel C. Salvoza ... Natalia Rosso
    Published: April 30, 2020 Explor Med. 2020;1:51-74
    DOI: https://doi.org/10.37349/emed.2020.00005
    This article belongs to the special issue Exploring NAFLD/NASH
    View:1851
    Download:33
    Open Access
    Original Article
    Identifying factors associated with opioid cessation in a biracial sample using machine learning
    Aim: Racial disparities in opioid use disorder (OUD) management exist, however, and there is limited research on factors that influence opioid cessation in different population groups. Methods: ...
    Jiayi W. Cox ... Lindsay A. Farrer
    Published: February 29, 2020 Explor Med. 2020;1:27-41
    DOI: https://doi.org/10.37349/emed.2020.00003
    This article belongs to the special issue The Biological Basis of Substance Use Disorders
    View:1362
    Download:37
    Times Cited: 0
    Open Access
    Review
    Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions
    Retinopathy of prematurity (ROP) is a blinding morbidity of preterm infants, which represents a significant clinical problem, accounting for up to 40% of all childhood blindness. ROP dis...
    Lara Carroll, Leah A. Owen
    Published: February 29, 2020 Explor Med. 2020;1:4-26
    DOI: https://doi.org/10.37349/emed.2020.00002
    View:1009
    Download:31
    Times Cited: 0
    Open Access
    Review
    PNPLA3 gene and kidney disease
    Chronic kidney disease (CKD) is a disease regularly seen in clinical practice. At present, CKD is described as a change of kidney structure and/or function and it is classified in relation to cause,...
    Alessandro Mantovani, Chiara Zusi
    Published: February 29, 2020 Explor Med. 2020;1:42-50
    DOI: https://doi.org/10.37349/emed.2020.00004
    View:846
    Download:12
    Open Access
    Review
    Perspectives of nonalcoholic fatty liver disease research: a personal point of view
    Rational government of patient fluxes from primary care to hepatology clinic is a priority of nonalcoholic fatty liver disease (NAFLD) research. Estimating pre-test probability of disease, risk of f...
    Amedeo Lonardo, Stefano Ballestri
    Published: June 29, 2020 Explor Med. 2020;1:85-107
    DOI: https://doi.org/10.37349/emed.2020.00007
    This article belongs to the special issue Exploring NAFLD/NASH
    View:825
    Download:26
    Open Access
    Review
    Nonalcoholic fatty liver disease and portal hypertension
    Nonalcoholic fatty liver disease (NAFLD) is a substantial and growing problem worldwide and has become the second most common indication for liver transplantation as it may progress to cirrhosis and...
    Marvin Ryou ... Gyorgy Baffy
    Published: June 29, 2020 Explor Med. 2020;1:149-169
    DOI: https://doi.org/10.37349/emed.2020.00011
    This article belongs to the special issue Exploring NAFLD/NASH
    View:807
    Download:19
    Times Cited: 0
    Open Access
    Review
    Understanding cardiac systolic performance beyond left ventricular ejection fraction
    Left ventricular ejection fraction is the critical parameter used for heart failure classification, decision making and assessing prognosis. It is defined as a volumetric ratio and is essentially a ...
    Elena-Laura Antohi, Ovidiu Chioncel
    Published: April 30, 2020 Explor Med. 2020;1:75-84
    DOI: https://doi.org/10.37349/emed.2020.00006
    View:759
    Download:17
    Times Cited: 0
    Open Access
    Original Article
    Placental OPRM1 DNA methylation and associations with neonatal opioid withdrawal syndrome, a pilot study
    Aim: Epigenetic variation of DNA methylation of the mu-opioid receptor gene (OPRM1) has been identified in the blood and saliva of individuals with opioid use disorder (OUD) and infants with neonat...
    Elisha M. Wachman ... Huiping Zhang
    Published: June 29, 2020 Explor Med. 2020;1:124-135
    DOI: https://doi.org/10.37349/emed.2020.00009
    This article belongs to the special issue The Biological Basis of Substance Use Disorders
    View:694
    Download:14
    Times Cited: 0
    Open Access
    Original Article
    Reduction of endoglin receptor impairs mononuclear cell-migration
    Aim: To test if the impairment of mononuclear cell (MNC) migration in patients with hereditary hemorrhagic telangiectasia (HHT) is due to the reduction of the endoglin (ENG) receptor on the cell su...
    Zhenying Han ... Hua Su
    Published: June 29, 2020 Explor Med. 2020;1:136-148
    DOI: https://doi.org/10.37349/emed.2020.00010
    View:693
    Download:16
    Times Cited: 0
    Open Access
    Review
    Type 2 diabetes and cancer: problems and suggestions for best patient management
    Diabetes and cancer are widespread worldwide and the number of subjects presenting both diseases increased over the years. The management of cancer patients having diabetes represents a challenge no...
    Agostino Milluzzo ... Laura Sciacca
    Published: August 31, 2020 Explor Med. 2020;1:184-204
    DOI: https://doi.org/10.37349/emed.2020.00013
    This article belongs to the special issue Exploring Type 2 Diabetes Mellitus
    View:631
    Download:4
    Times Cited: 0
    Open Access
    Perspective
    Visual communication and learning from COVID-19 to advance preparedness for pandemics
    The currently ongoing coronavirus disease 19 (COVID-19) pandemic has affected globally human health and economy. Research in progress has shown facts associated with this disease and raised question...
    José de la Fuente ... Christian Gortázar
    Published: August 31, 2020 Explor Med. 2020;1:244-247
    DOI: https://doi.org/10.37349/emed.2020.00016
    View:613
    Download:13
    Times Cited: 0
    Open Access
    Review
    Non-alcoholic fatty liver disease and transient elastography
    Nonalcoholic fatty liver disease (NAFLD) is a serious condition that can lead to fibrosis, cirrhosis, and hepatocellular carcinoma. NAFLD is associated with metabolic syndrome (MetS) and all of its ...
    Ivana Mikolasevic ... Sandra Milic
    Published: August 31, 2020 Explor Med. 2020;1:205-217
    DOI: https://doi.org/10.37349/emed.2020.00014
    This article belongs to the special issue Exploring NAFLD/NASH
    View:603
    Download:6
    Times Cited: 0
    Open Access
    Review
    Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease
    The prevalence of nonalcoholic or more recently re-defined metabolic associated fatty liver disease (MAFLD) is rapidly growing worldwide. It is characterized by hepatic fat accumulation exceeding 5&...
    Marica Meroni ... Paola Dongiovanni
    Published: August 31, 2020 Explor Med. 2020;1:218-243
    DOI: https://doi.org/10.37349/emed.2020.00015
    This article belongs to the special issue Exploring NAFLD/NASH
    View:594
    Download:16
    Times Cited: 0
    Open Access
    Review
    The therapeutic potential of C-C chemokine receptor antagonists in nonalcoholic steatohepatitis
    Pooled prevalence of nonalcoholic fatty liver disease (NAFLD) globally is about 25%. Nonalcoholic steatohepatitis (NASH) with advanced fibrosis has been linked with substantial morbidity...
    Michael Doulberis ... Stergios A. Polyzos
    Published: August 31, 2020 Explor Med. 2020;1:170-183
    DOI: https://doi.org/10.37349/emed.2020.00012
    This article belongs to the special issue Exploring NAFLD/NASH
    View:566
    Download:7
    Times Cited: 0
    Open Access
    Meta-Analysis
    GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis
    Aim: Recent randomized controlled trials (RCTs) have tested the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) to specifically treat non-alcoholic fatty liver disease (NAFLD). We ...
    Alessandro Mantovani ... Giovanni Targher
    Published: June 29, 2020 Explor Med. 2020;1:108-123
    DOI: https://doi.org/10.37349/emed.2020.00008
    This article belongs to the special issue Exploring Type 2 Diabetes Mellitus
    View:545
    Download:11
    Times Cited: 0
    Open Access
    Editorial
    Welcome message from the Editor-in-Chief
    Lindsay A. Farrer
    Published: February 29, 2020 Explor Med. 2020;1:1-3
    DOI: https://doi.org/10.37349/emed.2020.00001
    View:539
    Download:18
    Times Cited: 0
    Open Access
    Review
    Role of acetylation in nonalcoholic fatty liver disease: a focus on SIRT1 and SIRT3
    Nonalcoholic fatty liver disease (NAFLD) has become the most prevalent liver chronic disease worldwide. The pathogenesis of NAFLD is complex and involves many metabolic enzymes and multiple pathways...
    Fatiha Nassir
    Published: August 31, 2020 Explor Med. 2020;1:248-258
    DOI: https://doi.org/10.37349/emed.2020.00017
    This article belongs to the special issue Exploring NAFLD/NASH
    View:518
    Download:7
    Times Cited: 0